Details for Patent: 8,114,833

Which drugs does patent 8,114,833 protect, and when does it expire?

Patent 8,114,833 protects OZEMPIC, SAXENDA, and VICTOZA, and is included in three NDAs.

Protection for SAXENDA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-five patent family members in nineteen countries.

Summary for Patent: 8,114,833

Title:	Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Abstract:	The present invention relates to pharmaceutical formulations comprising a peptide and propylene glycol, to methods of preparing such formulations, and to uses of such formulations in the treatment of diseases and conditions for which use of the peptide contained in such formulations is indicated. The present invention further relates to methods for reducing the clogging of injection devices by a peptide formulation and for reducing deposits on production equipment during production of a peptide formulation.
Inventor(s):	Pedersen; Tina Bjeldskov (Smorum, DK), Bonde; Claude (Lyngby, DK), Engelund; Dorthe Kot (Holte, DK)
Assignee:	Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:	11/435,977
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,114,833
Patent Claim Types: see list of patent claims	Formulation; Compound; Use; Device;

Drugs Protected by US Patent 8,114,833

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-001	Dec 5, 2017		RX	Yes	Yes			Y
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-002	Apr 9, 2019		RX	Yes	Yes			Y
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-003	Mar 28, 2022		RX	Yes	Yes			Y
Novo	SAXENDA	liraglutide recombinant	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014		RX	Yes	Yes					Y
Novo Nordisk Inc	VICTOZA	liraglutide recombinant	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010		RX	Yes	Yes					Y

Foreign Priority and PCT Information for Patent: 8,114,833

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Denmark	2003 01719	Nov 20, 2003

International Family Members for US Patent 8,114,833

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2004290862
Brazil	PI0416743
Canada	2545034
China	102784386
China	104826116
China	113304250